Literature DB >> 16444993

Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas.

Kenji Torii1, Naohiro Tsuyuguchi, Joji Kawabe, Ichiro Sunada, Mitsuhiro Hara, Susumu Shiomi.   

Abstract

OBJECTIVE: The uptake of L-methyl-11C-methionine (MET) by gliomas is greater than that by intact tissue, making methionine very useful for evaluation of tumor extent. If the degree of malignancy of brain tumors can be evaluated by MET-PET, the usefulness of MET-PET as a means of diagnosing brain tumors will increase.
METHODS: We performed this study on 67 glioma patients between 3 and 69 years of age (36 males and 31 females). Tumors included diffuse astrocytoma, anaplastic astrocytoma, glioblastoma, ependymoma, oligodendroglioma, medulloblastoma, dysembryoplastic neuroepithelial tumor, choroid plexus papilloma, central neurocytoma, optic glioma, gliomatosis cerebri, pleomorphic xanthoastrocytoma, and ganglioglioma. Tumor activity and degree of malignancy were evaluated using Ki-67LI (LI: labeling index) and Kaplan-Meier survival curves. The correlations between methionine uptake and tumor proliferation (tumor versus contralateral gray matter ratio (T/N) and Ki-67LI) were determined for the group of all subjects. The existence of significant correlations between T/N and Ki-67LI and between SUV and Ki-67LI was determined for astrocytic tumors. Receiver operating characteristics (ROC) analysis of T/N and standardized uptake value (SUV) was performed for the group of astrocytic tumors. We also determined the ROC cut-off levels to ensure high accuracy of the analysis.
RESULTS: For the 67 cases of glioma, the degree of accumulation was variable. Ki-67LI differed significantly between the high-grade group and low-grade group at T/N levels between 1.5 and 1.8 on analysis using tumor proliferative potential (p = 0.019-0.031). The prognosis differed significantly between the high-grade and low-grade groups when T/N was in the range of 1.6-1.8 (p = 0.028-0.032). The accuracy thus calculated was highest (85.7%) when T/N was 1.5 as determined by ROC analysis.
CONCLUSIONS: When analysis was confined to cases of astrocytic tumor, a correlation was noted between methionine accumulation and Ki-67LI. For the astrocytic tumors, T/N ratio seemed to be more useful as a diagnostic indicator than SUV. The cut-off level of T/N ratio for distinction between high-grade and low-grade astrocytoma appears to lie between 1.5 and 1.6.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16444993     DOI: 10.1007/BF02985116

Source DB:  PubMed          Journal:  Ann Nucl Med        ISSN: 0914-7187            Impact factor:   2.668


  20 in total

1.  Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas.

Authors:  Cécile Colavolpe; Philippe Metellus; Julien Mancini; Maryline Barrie; Céline Béquet-Boucard; Dominique Figarella-Branger; Olivier Mundler; Olivier Chinot; Eric Guedj
Journal:  J Neurooncol       Date:  2011-12-15       Impact factor: 4.130

2.  Concurrent temozolomide and dose-escalated intensity-modulated radiation therapy in newly diagnosed glioblastoma.

Authors:  Christina I Tsien; Doris Brown; Daniel Normolle; Matthew Schipper; Morand Piert; Larry Junck; Jason Heth; Diana Gomez-Hassan; Randall K Ten Haken; Thomas Chenevert; Yue Cao; Theodore Lawrence
Journal:  Clin Cancer Res       Date:  2011-11-07       Impact factor: 12.531

Review 3.  Molecular imaging of gliomas with PET: opportunities and limitations.

Authors:  Christian la Fougère; Bogdana Suchorska; Peter Bartenstein; Friedrich-Wilhelm Kreth; Jörg-Christian Tonn
Journal:  Neuro Oncol       Date:  2011-07-13       Impact factor: 12.300

4.  Oligodendroglial component complicates the prediction of tumour grading with metabolic imaging.

Authors:  Osamu Manabe; Naoya Hattori; Shigeru Yamaguchi; Kenji Hirata; Kentaro Kobayashi; Shunsuke Terasaka; Hiroyuki Kobayashi; Hiroaki Motegi; Tohru Shiga; Keiichi Magota; Noriko Oyama-Manabe; Ken-ichi Nishijima; Yuji Kuge; Nagara Tamaki
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-03       Impact factor: 9.236

5.  MRI findings and pathological features in early-stage glioblastoma.

Authors:  Makoto Ideguchi; Koji Kajiwara; Hisaharu Goto; Kazutaka Sugimoto; Sadahiro Nomura; Eiji Ikeda; Michiyasu Suzuki
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

6.  [Molecular imaging in neurological diseases].

Authors:  M Reimold; C la Fougère
Journal:  Radiologe       Date:  2016-07       Impact factor: 0.635

Review 7.  Discrimination between primary low-grade and high-grade glioma with 11C-methionine PET: a bivariate diagnostic test accuracy meta-analysis.

Authors:  Anna Falk Delgado; Alberto Falk Delgado
Journal:  Br J Radiol       Date:  2018-01-22       Impact factor: 3.039

8.  FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading.

Authors:  Gabriele Pöpperl; Friedrich W Kreth; Jan H Mehrkens; Jochen Herms; Klaus Seelos; Walter Koch; Franz J Gildehaus; Hans A Kretzschmar; Jörg C Tonn; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-01       Impact factor: 9.236

9.  11C-acetate PET in the evaluation of brain glioma: comparison with 11C-methionine and 18F-FDG-PET.

Authors:  Y Yamamoto; Y Nishiyama; N Kimura; R Kameyama; N Kawai; T Hatakeyama; M Kaji; M Ohkawa
Journal:  Mol Imaging Biol       Date:  2008-06-10       Impact factor: 3.488

10.  Association of 11C-methionine PET uptake with site of failure after concurrent temozolomide and radiation for primary glioblastoma multiforme.

Authors:  Irwin H Lee; Morand Piert; Diana Gomez-Hassan; Larry Junck; Lisa Rogers; James Hayman; Randall K Ten Haken; Theodore S Lawrence; Yue Cao; Christina Tsien
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-10-01       Impact factor: 7.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.